<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The neuroprotector properties of cyclopentyladenosine (CPA), an <z:chebi fb="3" ids="16335">adenosine</z:chebi> receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>, were studied on a model of focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> in rats (reproducing a clinical <z:mpath ids='MPATH_596'>pathological process</z:mpath> in humans) </plain></SENT>
<SENT sid="1" pm="."><plain>The model of the focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> in rats was induced by intravasal occlusion of left carotid artery, middle cerebral artery, and by bilateral occlusion of both carotid arteries </plain></SENT>
<SENT sid="2" pm="."><plain>CPA was introduced by intracerebroventricular injections in a dose of 25 micrograms/kg, 60 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> induction </plain></SENT>
<SENT sid="3" pm="."><plain>The protective effect was judged by comparing the neurological and histopathological disturbances in the control (untreated <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>) and on the CPA background </plain></SENT>
<SENT sid="4" pm="."><plain>CPA injections produced a pronounced neuroprotector effect on the minimum-invasive focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> model in rats </plain></SENT>
</text></document>